Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits
2021 Gastrointestinal Cancers SymposiumRomain Cohen, MD, PhD, of the Mayo Clinic and Sorbonne University, discusses a post-hoc analysis of phase III results from the CALGB/SWOG 80702 study, which showed that adding the number of tumor deposits, a negative prognostic factor, to the count of lymph node metastases may improve the accuracy of TNM staging (Abstract 10).
Related Videos
Rutika Mehta, MD, MPH, on Gastric Cancer: Adjuvant Chemotherapy With S-1 and Docetaxel
Rutika Mehta, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the 3-year regression-free and overall survival results from the JACCRO study, wh...
Talia Golan, MD, on Pancreatic Cancer: Olaparib for BRCA-Mutated Disease
Talia Golan, MD, of the Oncology Institute, Sheba Medical Center, discusses phase III results from the POLO trial, which explored the question of whether maintenance olaparib...
Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib
Richard S. Finn, MD, of the UCLA Medical Center, discusses updated results from the IMbrave 150 study, which showed atezolizumab plus bevacizumab provides the longest overall...
Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment
Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant thera...
Kai-Keen Shiu, MD, PhD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Microsatellite Instability–High Disease
Kai-Keen Shiu, MD, PhD, of the University College Hospital NHS Foundation Trust - London, discusses an interim analysis of PFS 2 results (defined as...
